Inventor
GARLAND WILLIAM A
US45 patents
⚠️ This page may combine multiple inventors who share the name “GARLAND WILLIAM A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TOSK INC
14 patentsUS7998967B2Aug 16, 2011
Methotrexate adjuvants to reduce toxicity and methods for using the same
TOSK INC15 citations91
USRE48253EOct 13, 2020
Methotrexate adjuvants to reduce toxicity and methods for using the same
TOSK INC5 citations82
US9382287B2Jul 5, 2016
Methotrexate adjuvants to reduce toxicity and methods for using the same
TOSK INC5 citations82
US11945803B2Apr 2, 2024
Modulators of RAS GTPase
TOSK INC3 citations71
US11446303B2Sep 20, 2022
Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
TOSK INC3 citations67
US12508265B2Dec 30, 2025
Methods and compositions for reducing radiation induced toxicity
TOSK INC0 citations60
US12419893B2Sep 23, 2025
Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine
TOSK INC0 citations60
US12194043B2Jan 14, 2025
Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
TOSK INC0 citations60
US12109222B2Oct 8, 2024
Methods and compositions for treating mucositis
TOSK INC0 citations60
US12486255B2Dec 2, 2025
Modulators of RAS GTPase
TOSK INC0 citations59
US9468613B2Oct 18, 2016
Doxorubicin adjuvants to reduce toxicity and methods for using the same
TOSK INC0 citations51
US12528796B2Jan 20, 2026
Modulators of RAS GTPase
TOSK INC0 citations48
US11390626B2Jul 19, 2022
Pyrazolopyrimidine modulators of RAS GTPase
TOSK INC0 citations48
US10660318B2May 26, 2020
Non-mammalian RAS transgenic animal model
TOSK INC0 citations44
SABBADINI ROGER A
11 patentsUS8614103B2Dec 24, 2013
Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
SABBADINI ROGER A6 citations81
US8158124B2Apr 17, 2012
Compositions and methods for binding lysophosphatidic acid
SABBADINI ROGER A10 citations81
US8067549B2Nov 29, 2011
Humanized antibodies and compositions for binding sphingosine-1-phosphate
SABBADINI ROGER A4 citations73
US8604172B2Dec 10, 2013
Humanized antibody compositions and methods for binding lysophosphatidic acid
SABBADINI ROGER A5 citations72
US8796429B2Aug 5, 2014
Bioactive lipid derivatives, and methods of making and using same
SABBADINI ROGER A2 citations62
US8222373B2Jul 17, 2012
Humanized antibodies and compositions for binding sphingosine-1-phosphate
SABBADINI ROGER A1 citations62
US8444970B2May 21, 2013
Compositions and methods for treating ocular diseases and conditions
SABBADINI ROGER A2 citations60
US9217749B2Dec 22, 2015
Immune-derived moieties reactive against lysophosphatidic acid
SABBADINI ROGER A1 citations52
US9163091B2Oct 20, 2015
Compositions and methods for binding lysophosphatidic acid
SABBADINI ROGER A0 citations45
US9274129B2Mar 1, 2016
Methods and reagents for detecting bioactive lipids
SABBADINI ROGER A0 citations41
US9181331B2Nov 10, 2015
Pharmaceutical compositions for binding sphingosine-1-phosphate
SABBADINI ROGER A0 citations35
CENTAUR PHARMACEUTICALS INC
8 patentsUS6258852B1Jul 10, 2001
Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
CENTAUR PHARMACEUTICALS INC20 citations90
US6486349B1Nov 26, 2002
Amide therapeutics and methods for treating inflammatory bowel disease
CENTAUR PHARMACEUTICALS INC49 citations89
US6271265B1Aug 7, 2001
Amide therapeutics for the treatment of inflammatory bowel disease
CENTAUR PHARMACEUTICALS INC9 citations71
US6083989AJul 4, 2000
Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
CENTAUR PHARMACEUTICALS INC14 citations71
US5955506ASep 21, 1999
Benzamides for neurodegenerative disorder treatment
CENTAUR PHARMACEUTICALS INC6 citations70
US6194465B1Feb 27, 2001
Benzamide therapeutics for the treatment of inflammatory bowel disease
CENTAUR PHARMACEUTICALS INC2 citations61
US6545056B1Apr 8, 2003
Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
CENTAUR PHARMACEUTICALS INC5 citations60
US6140369AOct 31, 2000
Benzamides for neurodegenerative disorder treatment
CENTAUR PHARMACEUTICALS INC3 citations59
LPATH INC
6 patentsUS7829674B2Nov 9, 2010
Compositions and methods for binding sphingosine-1-phosphate
LPATH INC20 citations91
US8025877B2Sep 27, 2011
Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate
LPATH INC5 citations73
US8026342B2Sep 27, 2011
Compositions and methods for binding sphingosine-1-phosphate
LPATH INC2 citations61
US7956173B2Jun 7, 2011
Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate
LPATH INC0 citations51
US7794713B2Sep 14, 2010
Compositions and methods for the treatment and prevention of hyperproliferative diseases
LPATH INC0 citations45
US8361465B2Jan 29, 2013
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
LPATH INC0 citations41
GARLAND WILLIAM A
3 patentsUS9061038B2Jun 23, 2015
Doxorubicin adjuvants to reduce toxicity and methods for using the same
GARLAND WILLIAM A5 citations82
US8853227B2Oct 7, 2014
Methotrexate adjuvants to reduce toxicity and methods for using the same
GARLAND WILLIAM A8 citations81
US8227517B2Jul 24, 2012
Doxorubicin adjuvants to reduce toxicity and methods for using the same
GARLAND WILLIAM A0 citations50